Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for kids with retinoblastoma: tailored therapies aim to save lives and sight

NCT ID NCT00186888

Disease control Sponsor: St. Jude Children's Research Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tested personalized treatments for children with retinoblastoma, a rare eye cancer. Researchers divided 107 participants into groups based on whether one or both eyes were affected and how advanced the cancer was. They used combinations of chemotherapy drugs like vincristine, carboplatin, and topotecan, along with surgery if needed, aiming to cure the cancer while preserving vision.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Vincristine, Carboplatin, Topotecan
What this could lead to
If successful, this study could improve how doctors personalize treatment for children with retinoblastoma, potentially increasing cure rates and saving more vision.
What could go wrong
This is an older completed study, so results may not reflect current best practices. Chemotherapy has side effects like infection risk and organ damage, and some children may still need eye removal.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

107 people

The number who actually took part.

Started

Apr 2005

Finished

Nov 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Must have newly diagnosed intraocular retinoblastoma, previously untreated. Patients previously diagnosed with unilateral retinoblastoma treated surgically (or with focal therapies), who develop asynchronous involvement of the contralateral eye, will be eligible for study. * Must have a life expectancy of at least 8 weeks. * Must have Performance Status (ECOG) of 0-2. * Patients must have an adequate liver function, as defined by bilirubin less than or equal to 3 x normal, and SGOT and SGPT less than or equal to 3x normal. * Patients must have adequate renal function as defined by serum creatinine less than or equal to 3x normal for age. * Legal guardians must sign an informed consent indicating that they are aware of this study, its possible benefits, and toxic side effects. Legal guardians will be given a copy of the consent form. Exclusion Criteria: * Previously treated patients * Presence of metastatic disease or orbital involvement * Patients must not have an invasive infection at time of protocol entry.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Intraocular retinoblastoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

intraocular retinoblastoma ocular cancer retina neoplasm retinal cancer retinoblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Retinal neoplasm Retinoblastoma

Contacts and locations

Locations

  • St. Jude Children's Research Hospital

    Memphis, Tennessee, 38105, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.